+65 3158 9940
1300 798 820
+64 9801 0299
ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
57 year old Lay Har has never been a smoker and has always considered herself relatively healthy, was shocked when she was diagnosed with Stage 4 Small Cell Lung Cancer in April this year, after experiencing some “discomfort” in her chest. She was scared by her diagnosis but has found support from fellow patients and
First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
Consultant Clinical Oncologist Dr Aqilah Othman says an ageing population, fewer and later pregnancies, a lack of physical activity, obesity and poor dietary habits may be contributing to a rising incidence of new breast cancer cases across Southeast Asia. To mark Breast Cancer Awareness Month 2023, the Sunway Medical Centre oncologist discusses the incidence of
SEA’s largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA) World Orphan Drug Alliance (WODA) now spans 152 countries. WODA offers a ‘one-stop’ solution for biotech companies
Singapore and Tilburg, Netherlands, August 28 2023: Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS) – the most common form of Motor Neurone Disease (MND) – in Australia and New Zealand. The therapy is
YONDELIS® (trabectedin) now PBS listed for Australian patients Listing described as “wonderful news” for patients living with rare lipo and leiomyo sarcomas YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 Singapore, 31 July 2023: AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now
Specialised Therapeutics Asia will partner with CTTQ-Akeso to commercialise a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia.
This article is contributed by Dr Choo Su Pin, a senior medical oncologist at Curie Oncology who specialises in gastrointestinal cancers.
Specialised Therapeutics is thrilled to announce the official opening of its Thailand office, as we continue our mission to provide specialist therapies to patients across South East Asia. We are determined to ensure our medicines reach as many eligible patients as possible – particularly in oncology, with almost 200,000 Thai residents diagnosed with cancer every year (*Globocan 2020).